We began our journey in 2007 as a one of the earliest pioneers in the field of oligonucleotide drugs, committed to the development of RNA interference (RNAi) technology and industrialization of oligonucleotide drugs. We have established oligonucleotide therapeutic platform that vertically integrates the complete set of technologies to support the full life cycle of oligonucleotide therapeutics from early R&D to commercialization. We have built a globally integrated oligonucleotide drug development capability and have constructed a rich siRNA drug pipeline through independent innovation, covering cardiovascular, metabolic, renal，liver other diseases, especially in the field of chronic disease treatment.
With a globally proprietary innovation R&D platform, we enabling encompass the full lifecycle technology of oligonucleotide drugs from early research to commercialization, including drug delivery, chemical modification, multi-target drug design, model-informed drug development, pharmacology research and manufacturing. Among them, our proprietary liver-targeted delivery platform RiboGalSTARTM, have advanced several products into the clinical phase Ⅱ stage, with excellent clinical validation of effectiveness and safety. Our partnership with Boehringer Ingelheim stands out as the sole platform-level partnership between a China-based biotech company and a global MNC in the RNAi space, reflecting the high degree of recognition by multinational pharmaceutical companies of our R&D platform and scientific research strength.
With a prospective global strategic layout, we have already established several R&D centers in Beijing and Suzhou, China, as well as in Europe.In the fierce global competition of biopharmaceuticals, under the form of “double-wheel drive” of globalized R&D strategy and internationalized management team, we have gathered a team with rich experience in multinational pharmaceuticals, so as to support our sustainable development and global competitiveness, and thus to promote China's oligonucleotide pharmaceutical industry to the forefront of the world.
